康华生物股价涨5.46%，南方基金旗下1只基金位居十大流通股东，持有86.17万股浮盈赚取360.19万元

Group 1 - The core viewpoint of the news is that Kanghua Biological has seen a significant increase in its stock price, rising by 5.46% to 80.78 CNY per share, with a trading volume of 295 million CNY and a turnover rate of 3.19%, resulting in a total market capitalization of 10.497 billion CNY [1] - Kanghua Biological, established on April 2, 2004, and listed on June 16, 2020, specializes in the comprehensive research, development, and operation of vaccines, with 99.99% of its main business revenue coming from non-immunization planning vaccines [1] Group 2 - Among the top ten circulating shareholders of Kanghua Biological, a fund under Southern Fund, the Southern CSI 1000 ETF (512100), has newly entered the list in the second quarter, holding 861,700 shares, which accounts for 0.71% of the circulating shares, with an estimated floating profit of approximately 3.6019 million CNY [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 64.953 billion CNY, achieving a year-to-date return of 25.52% and a one-year return of 66.59% [2]